HELTON RAMOS

Dr. HELTON RAMOS


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
CRCamila Lüdke Rossetti
Camila Lüdke Rossetti
JCJuliana Cazarin
Juliana Cazarin
FHFabio Hecht
Fabio Hecht
FBFabyan Esberard de Lima Beltrão
Fabyan Esberard de Lima Beltrão
AFAndrea Cláudia Freitas Ferreira
Andrea Cláudia Freitas Ferreira
DCDenise Pires de Carvalho
Denise Pires de Carvalho
Coronavirus disease 2019 (COVID-19) was characterized as a pandemic in March, 2020 by the World Health Organization. COVID-19 is a respiratory syndrome that can progress to acute respiratory distress syndrome, multiorgan dysfunction, and eventually death. Despite being considered a respiratory disease, it is known that other organs and systems can be affected in COVID-19, including the thyroid gland. Thyroid gland, as well as hypothalamus and pituitary, which regulate the functioning of most endocrine glands, express angiotensin-converting enzyme 2 (ACE2), the main protein that functions as a receptor to which SARS-CoV-2 binds to enter host cells. In addition, thyroid gland is extremely sensitive to changes in body homeostasis and metabolism. Immune system cells are targets for thyroid hormones and T3 and T4 modulate specific immune responses, including cell-mediated immunity, natural killer cell activity, the antiviral action of interferon (IFN) and proliferation of T- and B-lymphocytes. However, studies show that patients with controlled hypothyroidism and hyperthyroidism do not have a higher prevalence of COVID-19, nor do they have a worse prognosis when infected with the virus. On the other hand, retrospective observational studies, prospective studies, and case reports published in the last two years reported abnormal thyroid function related to acute SARS-CoV-2 infection or even several weeks after its resolution. Indeed, a variety of thyroid disorders have been documented in COVID-19 patients, including non-thyroidal illness syndrome (NTIS), subacute thyroiditis and thyrotoxicosis. In addition, thyroid disease has already been reported as a consequence of the administration of vaccines against SARS-CoV-2. Overall, the data revealed that abnormal thyroid function may occur during and in the convalescence post-COVID condition phase. Although the cellular and molecular mechanisms are not completely understood, the evidence suggests that the “cytokine storm” is an important mediator in this context. Thus, future studies are needed to better investigate the pathophysiology of thyroid dysfunction induced by COVID-19 at both molecular and clinical levels.

10 November 2021 in Thyroid®
Verified
Journal Article
Closed access
FBFabyan Esberard de Lima Beltrão
Fabyan Esberard de Lima Beltrão
DBDaniele Carvalhal de Almeida Beltrão
Daniele Carvalhal de Almeida Beltrão
GCGiulia Carvalhal de Almeida Cordeiro
Giulia Carvalhal de Almeida Cordeiro
FBFabricia Elizabeth de Lima Beltrão
Fabricia Elizabeth de Lima Beltrão
ABAmanda da Silva Brito
Amanda da Silva Brito
HRHELTON RAMOS
HELTON RAMOS
Background: Illness severity in patients infected with COVID-19 is variable. Methods: Here, we conducted an observational, longitudinal, and prospective cohort study to investigate serum thyroid hormone (TH) levels in adult COVID-19 patients, admitted between June and August 2020, and to determine whether they reflect the severity or mortality associated with the disease. Results: Two hundred forty-five patients [median age: 62 (49–75) years] were stratified into non-critical (181) and critically ill (64) groups. Fifty-eight patients (23.6%) were admitted to the intensive care unit, and 41 (16.7%) died. Sixteen (6.5%) exhibited isolated low levels of free triiodothyronine (fT3). fT3 levels were lower in critically ill compared with non-critical patients [fT3: 2.82 (2.46–3.29) pg/mL vs. 3.09 (2.67–3.63) pg/mL, p = 0.007]. Serum reverse triiodothyronine (rT3) was mostly elevated but less so in critically ill compared with non-critical patients [rT3: 0.36 (0.28–0.56) ng/mL vs. 0.51 (0.31–0.67) ng/mL, p = 0.001]. The univariate logistic regression revealed correlation between in-hospital mortality and serum fT3 levels (odds ratio [OR]: 0.47; 95% confidence interval [CI 0.29–0.74]; p = 0.0019), rT3 levels (OR: 0.09; [CI 0.01–0.49]; p = 0.006) and the product fT3 × rT3 (OR: 0.47; [CI 0.28–0.74]; p = 0.0026). Serum thyrotropin, free thyroxine, and fT3/rT3 values were not significantly associated with mortality and severity of the disease. A serum cutoff level of fT3 (≤2.6 pg/mL) and rT3 (≤0.38 ng/mL) was associated with 3.46 and 5.94 OR of mortality, respectively. We found three COVID-19 mortality predictors using the area under the receiver operating characteristic (ROC) curve (AUC score): serum fT3 (AUC = 0.66), rT3 (AUC = 0.64), and the product of serum fT3 × rT3 (AUC = 0.70). Non-thyroidal illness syndrome (fT3 < 2.0 pg/mL) was associated with a 7.05 OR of mortality ([CI 1.78–28.3], p = 0.005) and the product rT3 × fT3 ≤ 1.29 with an 8.08 OR of mortality ([CI 3.14–24.2], p < 0.0001). Conclusions: This prospective study reports data on the largest number of hospitalized moderate-to-severe COVID-19 patients and correlates serum TH levels with illness severity, mortality, and other biomarkers to critical illness. The data revealed the importance of early assessment of thyroid function in hospitalized patients with COVID-19, given the good prognostic value of serum fT3, rT3, and fT3 × rT3 product. Further studies are necessary to confirm these observations.

20 July 2020 in Endocrine
Verified
Journal Article
Closed access
PDF file
HRHELTON RAMOS
HELTON RAMOS
FHFabio Hecht
Fabio Hecht
ABAmandine Berdelou
Amandine Berdelou
IBIsabelle Borget
Isabelle Borget
SLSophie Leboulleux
Sophie Leboulleux
MSMartin Schlumberger
Martin Schlumberger

4 February 2022 in Brazilian Journal of Otorhinolaryngology
Verified
Journal Article
Open access
ISIsabela Matos da Silva
Isabela Matos da Silva
TNTaísa Quécia da Silva Nogueira
Taísa Quécia da Silva Nogueira
DCDeborah Nogueira Couto
Deborah Nogueira Couto
PLPaula Cristina Tanajura Meira Lima
Paula Cristina Tanajura Meira Lima
NBNatália Sampaio Carvalho Bonfim
Natália Sampaio Carvalho Bonfim
HRHELTON RAMOS
HELTON RAMOS
This study aims to investigate if a sampling method using virtual networks is feasible to survey AS adoption among this “hard-to-reach” population of Brazilian doctors. An online piloted 11-point structured survey questionnaire (designed using Googleforms®) probed the actual treatment patterns for adult patients with PTMCs, including treatment decision‐making nonoperative options, was undertaken between 10 November and 30 November 2020. Participants were reached by the mobile phone Application (APP) and a snowball sampling strategy was used to recruit a total of 4783 members (maximum number of potential reach), which is the total of doctors of the all 21 social media WhatsApp® groups. From a total of 4783 members (maximum number of potential reach), there were 657 (13.7%) doctors (actual reach) who clicked the web link of the questionnaire, out of whom 512 (10.7%) fully completed the online survey. Among the survey respondents, 361 were endocrinologists (70.5%) and 151 were surgeons (29.5%). Overall, for low-risk PTMCs in an elderly patient, 118 responders (23%) recommend AS, while 390 (76%) recommend immediate surgery as the management, including lobectomy (18.5%) and Total Thyroidectomy (58.2%). The present responders tended to recommend surgery for PTMCs that were located adjacent to the dorsal surface of the thyroid, were multiple, or raised the size during the follow-up. Using snowball sampling strategy as an innovative route to conduct surveys was feasible and applicable but the rate of response was still very low. Our data also suggests the need to investigate if AS is embraced by Brazilian doctors.

1 January 2025 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
LSLuciana Sant’aNa Leone de Souza
Luciana Sant’aNa Leone de Souza
RCRenata de Oliveira Campos
Renata de Oliveira Campos
JFJair de Souza Braga Filho
Jair de Souza Braga Filho
JJJoice dos Santos de Jesus
Joice dos Santos de Jesus
SASara Moreira Anunciação
Sara Moreira Anunciação
HRHELTON RAMOS
HELTON RAMOS
Selenium(Se) is an essential micronutrient for several immune and regulatory functions in the body. In thyroid tissue, Se contributes to the antioxidant system and is a crucial component of deiodinases, which are selenoproteins that participate in thyroid hormone metabolism. Additionally, this micronutrient exerts a significant impact on thyroid pathophysiology, as low levels of Se lead to reduced activity of glutathione peroxidase, a selenoprotein involved in antioxidative processes, thereby resulting in increased oxidative stress and damage to thyroid tissue. Selenium [...] ABSTRACT Selenium(Se) is an essential micronutrient for several immune and regulatory functions in the body. In thyroid tissue, Se contributes to the antioxidant system and is a crucial component of deiodinases, which are selenoproteins that participate in thyroid hormone metabolism. Additionally, this micronutrient exerts a significant impact on thyroid pathophysiology, as low levels of Se lead to reduced activity of glutathione peroxidase, a selenoprotein involved in antioxidative processes, thereby resulting in increased oxidative stress and damage to thyroid tissue. Selenium

1 February 2015 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
RCRenata de Oliveira Campos
Renata de Oliveira Campos
IBIasmin dos Santos Barreto
Iasmin dos Santos Barreto
LMLorena Rejane de Jesus Maia
Lorena Rejane de Jesus Maia
SRSara Cristina Lima Rebouças
Sara Cristina Lima Rebouças
TCTaíse Lima de Oliveira Cerqueira
Taíse Lima de Oliveira Cerqueira
HRHELTON RAMOS
HELTON RAMOS
Key words: Iodine; hypothyroidism; iodine deficiency, Brazil